Literature DB >> 15274855

[Stenting in primary pulmonary hypertension with compression of the left main coronary artery].

Susana Gómez Varela1, Pedro M Montes Orbe, Juan Alcíbar Villa, María V Egurbide, Iñigo Sainz, José I Barrenetxea Benguría.   

Abstract

Primary pulmonary hypertension is often associated with angina-like chest pain of uncertain etiology. Left main coronary artery compression by the pulmonary artery is a treatable cause of angina and should be considered in these patients. We describe a patient presenting with primary pulmonary hypertension, clinical angina and extrinsic compression of the left main coronary artery by the pulmonary artery, who was treated with direct stenting.

Entities:  

Mesh:

Year:  2004        PMID: 15274855

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  4 in total

1.  Extrinsic compression of the left coronary ostium by the pulmonary trunk: management in a case of Eisenmenger syndrome.

Authors:  Kothandam Sivakumar; Maruthanayagam Rajan; Gnanapragasam Francis; Krishnaswami Murali; Velayudhan Bashi
Journal:  Tex Heart Inst J       Date:  2010

Review 2.  Compression of adjacent anatomical structures by pulmonary artery dilation.

Authors:  Wael Dakkak; Adriano R Tonelli
Journal:  Postgrad Med       Date:  2016-03-07       Impact factor: 3.840

3.  Left Main Ostial Compression in a Patient with Pulmonary Hypertension: Dynamic Findings by IVUS.

Authors:  Luciana F Seabra; Henrique B Ribeiro; Pedro Gabriel Melo de Barros e Silva; Marcelo J Rodrigues; André G Spadaro; Fábio Conejo; Roger R Godinho; Sandro M M Faig; Thiago Andrade de Macedo; Luciana de P S Baptista; Marcos Valerio C de Resende; Valter Furlan; Expedito E Ribeiro
Journal:  Am J Case Rep       Date:  2015-12-23

4.  Eisenmenger syndrome with left main compression syndrome: a case report.

Authors:  Charlotte Johanna Cool; Fathy Fathini; Ibnu Adams; Aninka Saboe; Nuraini Yasmin Kusumawardhani; Astri Astuti; Achmad Fauzi Yahya
Journal:  BMC Cardiovasc Disord       Date:  2022-03-05       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.